Eating slowly and savoring your food can enhance satisfaction and prevent overeating
Oral Wegovy (Semaglutide Pill) The FDA approved the Wegovy pill in December 2025, giving patients an oral semaglutide option for weight management
Eligibility for Tirzepatide Treatment To be eligible for tirzepatide as a weight loss treatment (under the brand name Zepbound), you must meet one of the following criteria: A body mass index (BMI) of 30 or higher (classified as obese) A BMI of 27 or above, along with at least one weight-related complication such as high blood pressure, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease Your healthcare provider will assess your situation, including your medical history and current health status, to determine if tirzepatide is an appropriate treatment option
Inhibiting the JAK/STAT pathway to inhibit Th17 differentiation and expression of inflammatory factors (TNF-, IL-1, IL-6, IL-17, etc.) in the RA model, promote FLSs apoptosis, inhibit FLSs inflammatory apoptosis, and inhibit the expression of MMP-2 and MMP-9
